AU2000265054A1 - Lipid-peptide conjugates for treatment of cancer - Google Patents

Lipid-peptide conjugates for treatment of cancer

Info

Publication number
AU2000265054A1
AU2000265054A1 AU2000265054A AU6505400A AU2000265054A1 AU 2000265054 A1 AU2000265054 A1 AU 2000265054A1 AU 2000265054 A AU2000265054 A AU 2000265054A AU 6505400 A AU6505400 A AU 6505400A AU 2000265054 A1 AU2000265054 A1 AU 2000265054A1
Authority
AU
Australia
Prior art keywords
lipid
cancer
treatment
peptide conjugates
conjugates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2000265054A
Inventor
Manu Jaggi
Rama Mukherjee
Sudhanand Prasad
Rajan Sharma
Anu T. Singh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dabur Research Foundation
Original Assignee
Dabur Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dabur Research Foundation filed Critical Dabur Research Foundation
Publication of AU2000265054A1 publication Critical patent/AU2000265054A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2000265054A 2000-07-31 2000-07-31 Lipid-peptide conjugates for treatment of cancer Abandoned AU2000265054A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2000/020876 WO2002010193A1 (en) 2000-07-31 2000-07-31 Lipid-peptide conjugates for treatment of cancer

Publications (1)

Publication Number Publication Date
AU2000265054A1 true AU2000265054A1 (en) 2002-02-13

Family

ID=21741642

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2000265054A Abandoned AU2000265054A1 (en) 2000-07-31 2000-07-31 Lipid-peptide conjugates for treatment of cancer

Country Status (4)

Country Link
EP (1) EP1409519A1 (en)
AU (1) AU2000265054A1 (en)
CA (1) CA2405728A1 (en)
WO (1) WO2002010193A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1633380A4 (en) * 2003-06-19 2010-08-11 Yeda Res & Dev Antimicrobial and anticancer lipopeptides
US10487115B2 (en) * 2016-02-01 2019-11-26 University Of Canberra Proteinaceous compounds and uses therefor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL87055A (en) * 1988-07-08 1994-06-24 Illana Gozes Conjugates of vasoactive intestinal peptide (vip) and of fragments thereof and pharmaceutical compositions comprising them
US5217953A (en) * 1990-11-30 1993-06-08 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Vasoactive intestinal peptide antagonist
US5565424A (en) * 1994-02-07 1996-10-15 Ramot - University Authority For Applied Research And Industrial Development Ltd. Superactive VIP antagonists
JP2003530297A (en) * 1998-10-16 2003-10-14 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ， リプリゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ Combination therapy using VIP antagonists

Also Published As

Publication number Publication date
CA2405728A1 (en) 2002-02-07
EP1409519A1 (en) 2004-04-21
WO2002010193A1 (en) 2002-02-07

Similar Documents

Publication Publication Date Title
AU2001282717A1 (en) Cancer treatment by combination therapy
AU2002247304A1 (en) Anti-neovasculature preparations for cancer
AU2002222853A1 (en) Therapeutic compounds
AU2002252456A1 (en) Combination treatment of pancreatic cancer
AU2002328952A1 (en) Irinotecan for treatment of cancer
AU2001258117A1 (en) Supports for photosensitizer formulations
AU2001252599A1 (en) Remedies for cancer
AUPQ923100A0 (en) Treatment of prostate cancer
EP1176964B8 (en) Uses of et743 for treating cancer
AU2000258650A1 (en) 2-piperidone compounds for the treatment of cancer
AU2001277711A1 (en) Remedies for cisplatin-tolerant cancer
AU2001290165A1 (en) Components of canola for the treatment of cancer
AU2002351374A1 (en) Antibodies to treat cancer
AU2002308642A1 (en) Methods for treating cancer
AU2001214116A1 (en) Novel paclitaxel derivatives for the treatment of cancer
AU7636800A (en) Improved ricin-like toxins for treatment of cancer
AU2000265053A1 (en) Bombesin analogs for treatment of cancer
AU2001257325A1 (en) Cancer treatment
AU2001271284A1 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
AU5706500A (en) Medicinal compositions for treating colorectal cancer
AU5552400A (en) Treatment of cancer
AUPQ367699A0 (en) Treatment of cancer
AU2000265054A1 (en) Lipid-peptide conjugates for treatment of cancer
AU2001296224A1 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
GB0026015D0 (en) Cancer treatment